دورية أكاديمية
A nationwide Belgian survey on the influence of the new oral anticoagulants dabigatran and rivaroxaban on commonly used coagulation assays
| العنوان: | A nationwide Belgian survey on the influence of the new oral anticoagulants dabigatran and rivaroxaban on commonly used coagulation assays |
|---|---|
| المؤلفون: | Van Blerk, M, Bailleul, E, Chatelain, Bernard, Demulder, A, Devreese, K, Douxfils, J, Jochmans, K, Mullier, François, Wijns, W, Rida Soumali, M, Coucke, W, Vernelen, K, Van de Walle, P |
| المساهمون: | UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Laboratoire de biologie clinique |
| المصدر: | Journal of Thrombosis and Haemostasis, Vol. 113, no.1, p. 154-164 (2015) |
| بيانات النشر: | Wiley-Blackwell Publishing Ltd. |
| سنة النشر: | 2015 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Belgium France Germany actin analyzer anticoagulant agent antithrombin assay atrial fibrillation blood clotting blood clotting factor 10a inhibitor blood clotting test cerebrovascular accident clinical laboratory dabigatran dabigatran etexilate drug concentration embolism fibrinogen hemostasis hip human international normalized ratio knee arthroplasty laboratory monitoring parametric test partial thromboplastin time patient plasma prevention prothrombin time quality control rank sum test |
| الوصف: | Background: The new oral anticoagulants dabigatran etexilate (direct thrombin inhibitor, Pradaxa®, Boehringer Ingelheim) and rivaroxaban (direct factor Xa inhibitor, Xarelto®, Bayer) have been in clinical use for a few years for the prevention of thromboembolic events after elective hip- or knee-replacement surgery and for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Although these agents do not require monitoring, their presence can significantly influence coagulation assays, potentially leading to incorrect interpretation of test results. Aims: The Belgian national External Quality Assessment Scheme for blood coagulation organized a survey to investigate and illustrate to the clinical laboratories how these drugs affect their routine coagulation assays. Methods: All Belgian clinical laboratories routinely performing coagulation testing (n = 192) received five lyophilized plasma samples in April 2012. These samples consisted of a normal plasma pool spiked with dabigatran or rivaroxaban to the following final concentrations: 0, 100 ng/mL dabigatran, 250 ng/mL dabigatran, 120 ng/mL rivaroxaban, and 290 ng/mL rivaroxaban. The samples were purchased from Hyphen BioMed (Neuville surOise, France). Participants were requested to determine the following coagulation assays: prothrombin time (PT, seconds,% and INR), activated partial thromboplastin time (aPTT, seconds and ratio), fibrinogen and antithrombin. They were also required to mention the reagent and analyser used. Method-specific medians and robust standard deviations were calculated for all methods with ≥ 6 reported results (method of Tukey). Differences between methods were assessed by means of non parametric statistics (Wilcoxon test). Results: All but three laboratories participated in the survey (response rate of 98.4%). PT and aPTT: Both, dabigatran and rivaroxaban significantly prolonged the PT and aPTT in a concentration- and reagent-dependent manner. The PT was more influenced by rivaroxaban than by ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1538-7933 1538-7836 |
| العلاقة: | boreal:267212; http://hdl.handle.net/2078.1/267212Test; urn:ISSN:1538-7933; urn:EISSN:1538-7836 |
| الإتاحة: | http://hdl.handle.net/2078.1/267212Test |
| رقم الانضمام: | edsbas.2D76AD19 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15387933 15387836 |
|---|